



GOLD Combined Initial COPD Assessment & Management

GOLD ABE Assessment Tool



Initial Pharmacologic Treatment

INITIAL treatment - for patients with COPD who are naïve to maintenance pharmacological treatment



*Single inhaler therapy may be more convenient and effective than multiple inhalers; single inhalers improve adherence to treatment
Exacerbations refer to the number of exacerbations per year




Follow-up Pharmacological Treatment


2 Adjust Treatment

CONTINUE CURRENT TREATMENT
unless dyspnea or exacerbation(s) require optimization

• IF PERSISTENT DYSPNEA




• IF ONE OR MORE MODERATE OR SEVERE EXACERBATION



^aSingle inhaler therapy may be more convenient and effective than multiple inhalers; single inhalers improve adherence to treatment. ^bListed in order of approval in the US. ^cPatient-reported history of chronic bronchitis (chronic productive cough) for 3 months in the year up to screening, absent other known causes. Consider de-escalation of ICS if pneumonia or other considerable side-effects. In case of blood eos ≥ 300 cells/μL de-escalation is more likely to be associated with the development of exacerbations.

Management of Patients Currently on LABA+ICS



*Patient previously had exacerbations and responded to LABA+ICS treatment

Abbreviations
CAAT™ = Chronic Airways Assessment Test™; COPD = chronic obstructive pulmonary disease; eos = blood eosinophil count in cells per microliter; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroid; LABA = long-acting beta₂-agonist; LAMA = long-acting muscarinic antagonist; mMRC = modified Medical Research Council.

Reference
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 GOLD Report and Pocket Guide. Global strategy for prevention, diagnosis and management of COPD: 2026 Report. Accessed November 19, 2025. <https://goldcopd.org/2026-gold-report-and-pocket-guide/>

Important Information for Health Care Providers receiving this Presentation

- This information is being provided, as a professional courtesy, in response to your request
- This presentation is for use by the recipient institution or organization, its employees or agents, for medical education purposes only, and should not be edited or forwarded to other third parties
- You are not speaking on behalf of AstraZeneca and receipt of this presentation does not imply that you are
- This presentation should not be used for patient education
- The attached presentation may contain copyright protected work(s)
 - AstraZeneca has obtained permission from the copyright owner to use such work in this presentation
 - You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law